HOME >> MEDICINE >> NEWS
GL701 (prasterone) significantly reduces lupus flares

Philadelphia, Pa. - Oct. 31, 2000 - The incidence of debilitating flares or exacerbations that systemic lupus erythematosus (SLE or lupus) patients experience, some resulting in hospitalization, significantly declined with the use of GL701, according to a Phase III placebo-controlled, double-blind multicenter study conducted in Taiwan and presented at the 64th Annual Scientific Meeting of the American College of Rheumatology in Philadelphia. The drug used in this study is similar to Genelabs Technologies, Inc. (Nasdaq:GNLB) formulation of its investigational drug GL701. The study reported here today was conducted by Genelabs Biotechnology Co., Ltd. of Taiwan, a licensee of Genelabs Technologies, Inc.

"GL701 significantly reduced the percent of patients with flares. Since flares can punctuate the remission periods that lupus patients experience, the potential for this investigational drug to increase the duration of remission and decrease the number of flares that require hospitalization is an important therapeutic advance," says Deh-Ming Chang, M.D., coauthor of the study and Professor and Director of Rheumatology/Immunology at the Tri-Service General Hospital, Taipei, Taiwan, R.O.C.

In the study, Chang and his colleagues compared GL701 to placebo among 119 Taiwanese women with lupus. Patients were evaluated in a randomized double-blind comparison of GL701, 200 mg or placebo daily for 24 weeks. Investigators evaluated efficacy based on change in Systemic Lupus Activity Measure (SLAM) and change in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), which measure disease activity; physician and patient visual analog scales (VAS), which measure quality of life parameters; and percent of patients with definite flares.

Study results show that 18 percent of patients receiving GL701 experienced flares, compared to 34 percent of patients on placebo, a 46 percent reduction, which was significant (p=0.04). Moreover, no GL701 pa
'"/>

Contact: Beth Kaplan
212-601-8443
Porter Novelli
30-Oct-2000


Page: 1 2 3

Related medicine news :

1. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
2. Gastrointestinal disorders are associated significantly with sleepless nights
3. Landmark survey reveals asthma in children remains significantly out of control in the United States
4. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
5. Elderly cancer patients are significantly under-represented in cancer clinical trials
6. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
7. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
8. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer
9. New data show SPIRIVA significantly reduces COPD exacerbations and related health resource burden
10. GSKS Requip(R) (ropinirole HCl) significantly reduces periodic leg movements in patients with RLS
11. Two landmark studies show Taxotere (R) significantly improves survival in men with prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... ... March 23, 2017 , ... Altec ... The Resource Group as their 2016 Microsoft Dynamics Partner of the Year at ... CA. The award recognizes The Resource Group for their outstanding relationship with ...
(Date:3/23/2017)... ... March 23, 2017 , ... ChenMed, ... announced rapid completion of the strategic executive team expansion needed to further optimize ... the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... According to ... Americans, yet poor sleep is likely not the only cause of the sunken-eye look, ... that make you look older or in poor health are likely due to genetics, ...
(Date:3/23/2017)... PA (PRWEB) , ... March 23, 2017 , ... It’s ... That means many students are thinking about summer internships , which can be ... thereof). , The pros at Garden Media Group, a boutique public relations firm outside ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is now ... pricing. Verisys through its FACIS and other services maintains the largest ... , “We are delighted to be able to offer these various products to ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company ... unmet medical needs in rare diseases, today announced that ... on Monday, April 3 during ENDO 2017, the annual ... Florida , to discuss new data regarding its ... PTH and TransCon CNP). Ascendis is presenting ...
(Date:3/23/2017)... -- Prima BioMed has presented encouraging early ... in combination with Keytruda, with one of the six ... complete response. Recruitment in the second cohort is complete ... recruited by Q317. Preliminary efficacy data from the 15-patient, ... expected mid-year (recruitment in the 226-patient Phase IIb component ...
(Date:3/23/2017)... Piramal Pharma Solutions (PPS), ... nombramiento de Stuart E. Needleman como ... integrados completa para su base de clientes farmacéuticos ... el crecimiento y ejecución de las ofertas PPS. ... todas las actividades de desarrollo empresarial global para ...
Breaking Medicine Technology:
Cached News: